26,316,000 Shares of Common Stock BRICKELL BIOTECH, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • November 1st, 2021 • Brickell Biotech, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledNovember 1st, 2021 Company Industry JurisdictionBrickell Biotech, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to William Blair & Company, L.L.C., as representative (the “Representative”) of the several underwriters named in Schedule I hereto (each, an “Underwriter” and collectively, the “Underwriters”), an aggregate of 26,316,000 authorized but unissued shares (the “Firm Shares”) of common stock, par value $0.01 per share, of the Company (the “Common Stock”). The amount of the Firm Shares to be purchased by the Underwriters is set forth opposite each Underwriter’s name, as applicable, on Schedule I hereto. The Company also proposes to sell to the Underwriters, at the option of the Representative, up to an additional 3,947,400 shares of Common Stock (the “Option Shares”). The Firm Shares and the Option Shares are hereinafter referred to collectively as the “Shares” or the “Securities”.
11,290,323 Shares of Common Stock BRICKELL BIOTECH, INC. AMENDED AND RESTATED UNDERWRITING AGREEMENTUnderwriting Agreement • July 22nd, 2021 • Brickell Biotech, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledJuly 22nd, 2021 Company Industry JurisdictionBrickell Biotech, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to H.C. Wainwright & Co., LLC, as representative (the “Representative”) of the several underwriters named in Schedule I hereto (each, an “Underwriter” and collectively, the “Underwriters”), an aggregate of 11,290,323 authorized but unissued shares (the “Firm Shares”) of common stock, par value $0.01 per share, of the Company (the “Common Stock”). The amount of the Firm Shares to be purchased by the Underwriters is set forth opposite each Underwriter’s name, as applicable, on Schedule I hereto. The Company also proposes to sell to the Underwriters, at the option of the Representative, up to an additional 1,693,548 shares of Common Stock (the “Option Shares”). The Firm Shares and the Option Shares are hereinafter referred to collectively as the “Shares” or the “Securities”. This Amended and Restated Underwriting Agreement amends, restates and supe
FENNEC PHARMACEUTICALS INC. UNDERWRITING AGREEMENT 2,352,950 Common SharesUnderwriting Agreement • December 11th, 2017 • Fennec Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledDecember 11th, 2017 Company Industry JurisdictionFennec Pharmaceuticals Inc., a British Columbia corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters,” or each, an “Underwriter”), for whom Wedbush Securities Inc. is acting as the representative (the “Representative”), an aggregate of 2,352,950 authorized but unissued common shares (the “Firm Shares”), no par value (the “Common Stock”), of the Company. The Company also proposes to sell to the Underwriters, upon the terms and conditions set forth in Section 4 hereof, up to an additional 352,942 shares of Common Stock (the “Option Shares”). The Firm Shares and the Option Shares are hereinafter collectively referred to as the “Shares.” The Company and the Underwriters hereby confirm their agreement as follows:
Form of Underwriting Agreement [ ] Shares HopFed Bancorp, Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • May 25th, 2010 • Hopfed Bancorp Inc • Savings institution, federally chartered • Illinois
Contract Type FiledMay 25th, 2010 Company Industry JurisdictionHopFed Bancorp, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) for whom Howe Barnes Hoefer & Arnett, Inc. is acting as representative (the “Representative”) an aggregate of [ ] shares (the “Firm Shares”) of the common stock, $0.01 par value per share, of the Company (“Common Stock”). The Company also proposes to sell to the several Underwriters, for the sole purpose of covering over-allotments, if any, in connection with the sale of the Firm Shares, at the option of the Underwriters, up to an additional [ ] shares of Common Stock (the “Option Shares”). The Firm Shares and the Option Shares are hereinafter referred to collectively as the “Shares.”